Compare TCI & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | OABI |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.6M | 294.3M |
| IPO Year | 1994 | 2021 |
| Metric | TCI | OABI |
|---|---|---|
| Price | $38.97 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 55.5K | ★ 2.1M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | 6.56 |
| EPS | N/A | N/A |
| Revenue | ★ $49,060,000.00 | $18,666,000.00 |
| Revenue This Year | N/A | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $31.48 | $1.32 |
| 52 Week High | $59.65 | $5.43 |
| Indicator | TCI | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 51.56 |
| Support Level | $39.05 | $1.71 |
| Resistance Level | $41.67 | $5.43 |
| Average True Range (ATR) | 1.78 | 0.33 |
| MACD | 0.34 | -0.13 |
| Stochastic Oscillator | 71.62 | 4.28 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.